Learn More
BACKGROUND There is increasing evidence that the immune system produces a humoral response to cancer-derived antigens. This study assessed the diagnostic potential of autoantibodies to multiple known tumour-associated proteins. PATIENTS AND METHODS Sera from normal controls (n = 94), primary breast cancer patients (n = 97) and patients with ductal(More)
BACKGROUND Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may allow earlier diagnosis. We report the clinical validation of an autoantibody panel in newly diagnosed patients with lung cancer (LC). PATIENTS AND METHODS Three cohorts of patients with newly(More)
Tumor-associated autoantibodies (AAbs) have been described in patients with lung cancer, and the EarlyCDT®-Lung test that measures such AAbs is available as an aid for the early detection of lung cancer in high-risk populations. Improvements in specificity would improve its cost-effectiveness, as well as reduce anxiety associated with false positive tests.(More)
PURPOSE We investigated the presence of autoantibodies as immunobiomarkers to a panel of tumor-associated antigens in a group of individuals with small cell lung cancer (SCLC), a disease group that has a poor overall cancer prognosis and therefore may benefit most from early diagnosis. EXPERIMENTAL DESIGN Sera from 243 patients with confirmed SCLC and(More)
BACKGROUND Publications on autoantibodies to tumour-associated antigens (TAAs) have failed to show either calibration or reproducibility data. The validation of a panel of six TAAs to which autoantibodies have been described is reported here. MATERIALS AND METHODS Three separate groups of patients with newly diagnosed lung cancer were identified, along(More)
A single channel EEG recording was made in 25 patients undergoing cardiac surgery and analysed using 5 different techniques--amplitude, cerebral function monitor, Fourier, Hjorth, and zero-crossing analyses. The results of the analyses were plotted as trend information on paper. These trends were studied for changes in the EEG during surgery. In the(More)
BACKGROUND The National Lung Screening Trial showed that CT screening for lung cancer led to a 20% reduction in mortality. However, CT screening has a number of disadvantages including low specificity. A validated autoantibody assay is available commercially (EarlyCDT®-Lung) to aid in the early detection of lung cancer and risk stratification in patients(More)
An assay employing a panel of tumor-associated antigens has been validated and is available commercially (EarlyCDT®-Lung) to aid the early detection of lung cancer by measurement of serum autoantibodies. The high throughput (HTP) strategy described herein was pursued to identify new antigens to add to the EarlyCDT-Lung panel and to assist in the development(More)
BACKGROUND Individuals with liver disease, and especially those with Hepatitis B or C, are at an increased risk of developing hepatocellular carcinoma (HCC) which is the third most common cause of cancer-related death worldwide. Inadequate screening tests largely account for presentation of advanced tumours and high mortality rates. Early detection of HCC(More)
  • Olivia Noble, Carly Shumaker, +6 authors William Poulin-Deltour
  • 2013
1 Acknowledgements We would like to thank our community partners, the Vermont Chapter of The Nature Conservancy and the Nature Conservancy of Canada, for their immense support and assistance throughout this semester. More specifically, we would like to acknowledge our deep appreciation for Marie-Michele Rousseau-Clair and Emily Boedecker, whose dedication,(More)